A next-generation, anti-CD19 enhanced CAR T-cell therapy that secretes interleukin-18 achieved a response in 81% of lymphoma patients who failed previous CAR T-cell therapy. Duration of response was 9 ...
I f your doctor has recommended chimeric antigen receptor (CAR) T-cell immunotherapy for large B-cell lymphoma (LBCL), you’ve likely already tried several standard treatments, and the cancer did not ...
GMP ActiveMax ® Human T Cell Activation/Expansion CD3/CD28 Beads are uniform 5.5 μm magnetic beads coated with an optimized mixture of GMP-grade mouse monoclonal antibodies targeting CD3 and CD28, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results